文献速递临床试验与 GCP

局部他克莫司改善乳腺癌相关淋巴水肿(TACLE试验):一项随机双盲安慰剂对照II/III期试验的研究方案

Topical tacrolimus for the amelioration of breast cancer-related lymphedema (TACLE Trial): a study protocol for a randomized, double-blind, placebo-controlled phase II/III trial.
PubMed 文献 · Trials · 2025-04-08

乳腺癌相关淋巴水肿影响15-30%的乳腺癌患者,由治疗相关炎症和纤维化所致,主要由CD4+ T细胞介导。本研究为多中心、双盲、随机安慰剂对照试验,拟纳入80例I-II期乳腺癌相关淋巴水肿女性,1:1随机接受0.1%他克莫司软膏或安慰剂软膏治疗12个月,主要结局为淋巴水肿体积变化。

要点

  • 乳腺癌相关淋巴水肿影响15-30%的乳腺癌患者,与CD4+ T细胞介导的炎症和纤维化有关。
  • TACLE试验为多中心、双盲、随机安慰剂对照II/III期试验,纳入80例I-II期乳腺癌相关淋巴水肿女性。
  • 参与者1:1随机接受0.1%他克莫司软膏或安慰剂软膏治疗12个月。

核心结论

  • 该试验旨在验证他克莫司减少淋巴水肿体积、纤维化和液体潴留并改善生活质量的假设,阳性结果可能使他克莫司成为乳腺癌相关淋巴水肿的标准治疗。

研究设计与样本

  • 多中心、双盲、随机安慰剂对照II/III期试验,纳入80例I期和II期乳腺癌相关淋巴水肿女性,1:1随机接受0.1%他克莫司软膏或安慰剂软膏治疗12个月。

主要发现

  • 主要结局为基线、6个月和12个月测量的淋巴水肿体积变化。
  • 次要结局包括通过SF-36、DASH和LYMPH-Q上肢问卷评估的生活质量、通过生物阻抗光谱测定的淋巴水肿指数、通过吲哚菁绿淋巴造影评估的淋巴功能和流量以及皮肤纤维化测量。
  • 评估在基线、3、6、9和12个月进行。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast cancer-related lymphedema is a chronic condition affecting 15-30% of breast cancer patients, resulting from treatment-related inflammation and fibrosis primarily mediated by CD4 + T-cells. Tacrolimus, an immunomodulator, has shown efficacy in reducing lymphedema in both animal models and an initial clinical trial. This study aims to validate these findings in a larger cohort, hypothesizing that tacrolimus will reduce lymphedema volume, fibrosis, and fluid retention while improving quality of life. METHODS: This multicenter, double-blinded, randomized placebo-controlled trial will enroll 80 women with breast cancer-related lymphedema stages I and II. Participants will be randomized 1:1 to receive either 0.1% tacrolimus ointment or a placebo ointment for 12 months. Primary outcome will be the change in lymphedema volume measured at baseline, 6 months, and 12 months. Secondary outcomes include quality of life assessed via SF- 36, DASH, and LYMPH-Q Upper Extremity questionnaires; lymphedema index via bioimpedance spectroscopy; lymphatic function and flow via indocyanine green lymphangiography; and skin fibrosis measurement. Assessments will take place at baseline, 3, 6, 9, and 12 months. DISCUSSION: This trial will provide robust data on the efficacy of topical tacrolimus in reducing BCRL volume and improving patient quality of life. Positive results could establish tacrolimus as a standard treatment for BCRL, potentially enhancing clinical outcomes for affected patients. The findings will also contribute to understanding the role of immunomodulation in lymphedema management. TRIAL REGISTRATION: This trial is registered with the EU Clinical Trials Information System (CTIS) under EU CT Number: 2023-503644 - 13-00 (approved 16.05.2024) and ClinicalTrials.gov under identifier NCT06306274 (registered 12.03.2024).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hansen FG, Jørgensen MG, Thomsen JB, et al. Topical tacrolimus for the amelioration of breast cancer-related lymphedema (TACLE Trial): a study protocol for a randomized, double-blind, placebo-controlled phase II/III trial. Trials. 2025. PMID: 40200322. doi:10.1186/s13063-025-08829-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。